

**In the Claims**

Please cancel original claims 1-40 and add the following new claims 41-60.

1. – 40. (Canceled)

41. (New) An isolated polypeptide having phosphatonin activity.

42. (New) The polypeptide of Claim 41 wherein said polypeptide has an activity selected from the group consisting of:

regulating sodium dependent phosphate co-transport;  
regulating renal 25-hydroxy vitamin D3-24-hydroxylase;  
regulating renal 25-hydroxy-D-1-a-hydroxylase; and  
regulating skeletal formation and/or mineralization.

43. (New) The polypeptide of Claim 41 having a molecular weight in a range of from about 53 to 60 kDa as measured on SDS-PAGE.

44. (New) The polypeptide of Claim 41 having a molecular weight of about 200 kDa as measured on a bis-tris SDS-PAGE at pH 7.

45. (New) The polypeptide of Claim 41 comprising SEQ ID NO: 2.

46. (New) A formulation comprising the polypeptide of Claim 45 and a pharmacologically acceptable excipient, diluent or carrier.

47. (New) An antibody that binds specifically to a polypeptide having phosphatonin activity.

48. (New) The antibody of Claim 47, wherein said antibody is a monoclonal antibody.

49. (New) The antibody of Claim 48, wherein said polypeptide comprises SEQ ID NO:2.

50 (New) A formulation, comprising:

an antibody which specifically binds a polypeptide having phosphatonin activity;

and

a pharmacologically acceptable carrier.

51. (New) The formulation of claim 50, wherein the polypeptide having phosphatonin activity comprises SEQ ID NO:2.

52. (New) An isolated polypeptide having phosphatonin activity and being further characterized by:

regulating sodium dependent phosphate co-transport;

regulating renal 25-hydroxy vitamin D3-24-hydroxylase;

regulating renal 25-hydroxy-D-1-a-hydroxylase; and

regulating skeletal formation and/or mineralization.

53. (New) The polypeptide of Claim 52 having a molecular weight in a range of from about 53 to 60 kDa as measured on SDS-PAGE.

54. (New) The polypeptide of Claim 52 having a molecular weight of about 200 kDa as measured on a bis-tris SDS-PAGE at pH 7.

55. (New) The polypeptide of claim 52 comprising SEQ ID NO: 2.

56. (New) A formulation comprising the polypeptide of Claim 55 and a pharmacologically acceptable excipient, diluent or carrier.

57. (New) An antibody that binds specifically to a polypeptide having phosphatonin activity and being further characterized by:

regulating sodium dependent phosphate co-transport;

regulating renal 25-hydroxy vitamin D3-24-hydroxylase;

regulating renal 25-hydroxy-D-1-a-hydroxylase; and

regulating skeletal formation and/or mineralization.

58. (New) The antibody of Claim 57, wherein said antibody is a monoclonal antibody.
59. (New) The antibody of Claim 57, wherein said antibody is a polyclonal antibody.